Catalent Expands Biologics Capabilities
PTSM: Pharmaceutical Technology Sourcing and Management
Expansions at Catalent’s Kansas City, MO, and Madison, WI facilities made in response to industry demand.
Catalent Pharma Solutions has announced the multi-site expansion of its analytical and process development capabilities for biologics including include an expansion of bioassay and protein characterization capabilities at its Kansas City, MO, facility, and additional integrated analytical capabilities at its Madison, WI, bio-manufacturing facility.
The investments were made in response to increased industry demand for large molecule analytical services, regulatory expectations around NBEs, and additional characterization requirements for biosimilars, the company reported in a Nov. 20, 2015 statement. The investment in Kansas City enables the facility to offer dual and complementary options for kinetic and quantitative binding assays for characterization and GMP testing.
The expansion at the Madison site will be operational by January 2016. The company has expanded process development capability at the Madison site, including integration of the Ambr 15 microbioreactor system into its cell line and upstream development.
Source: Catalent Pharma Solutions
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
